Viking Therapeutics stock surges 12% amid Novo Nordisk trial woes

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.20%

U.S. stocks showed mixed results, with notable gains and losses across various sectors. Broadcom led S&P gains while Momentus surged dramatically on NASDAQ.

BofA reinstates pharma coverage

Bank of America reviews 11 U.S. pharma stocks, highlighting growth potential and challenges amid patent cliffs and pricing pressures while recommending buy, neutral, and underperform ratings.

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.29%

U.S. stocks had a mixed performance with notable gains in technology and consumer sectors, while utilities and telecoms struggled. Some shares reached new highs and lows.

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.28%

Amgen falls after obesity study results

Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.70%

U.S. stock markets fell, driven by losses in Technology and Healthcare sectors, with notable declines in Amazon and Moderna; Palantir reached all-time highs.

Citi initiates coverage on 5 new biotech stocks

Citigroup added five biotech stocks, giving Buy ratings to Gilead and Vertex, while Amgen, Biogen, and Regeneron received Neutral ratings due to various market challenges.

RBC's top 10 questions and answers on biotech stocks

RBC Capital Markets reveals top 10 investor questions on biotech sector, focusing on FDA impact, major companies' strategies, upcoming trial data, and market sentiment.